| Date | Title | Description |
| 17.07.2026 | DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY | Highlights
Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI)
DMX-6... |
| 10.07.2026 | Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing | Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to driv... |
| 06.07.2026 | Patent cliff fuels Novartis’ $1.5bn swoop for London biotech | Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global drugmakers continue deploying billions into promising biotech firms ahead of an estimated $450bn wave of patent expiri... |
| 29.06.2026 | Andera Partners joins the European Life Sciences Coalition (ELSC) with the aim to support the mobilization of capital for life sciences innovation in Europe. | Andera Partners joins the European Life Sciences Coalition (ELSC), alongside Forbion, HealthCap, Novo Holdings, Omega Funds, Sofinnova Partners, Van Lanschot Kempen, VIB, BioInnovation Institute, 4BIO Capital, Cooley and Covington.
Launched... |
| 22.06.2026 | Bionyra Pharma Raises $165M in Series A Funding | Bionyra Pharma, a Paris, France- and Boston, MA-based clinical-stage biopharmaceutical company developing new biologics for immune-mediated inflammatory diseases, raised $165M in Series A funding.
The round was led by Jeito Capital and Sofi... |
| 22.06.2026 | Bionyra Pharma Raises $165 Million Series A To Advance Biologics For Inflammatory Diseases | Bionyra Pharma announced its launch and an oversubscribed $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Heal... |
| 01.06.2026 | P2 Science Secures $23M to Propel Green Chemistry Expansion | P2 Science, a green chemistry pioneer, raised $23 million in an oversubscribed funding round. Sofinnova Partners led this significant investment. The capital will accelerate commercial growth across multiple sectors. New markets include aro... |
| 26.05.2026 | P2 Science Raises $23M in Funding | P2 Science, Inc., a Woodbridge, CT-based green chemistry company turning sustainable feedstocks into high-performance ingredients, raised $23M in funding.
The round was led by Sofinnova Partners.
The company intends to use the funds to acce... |
| 26.05.2026 | P2 Science Raises $23 Million To Expand Green Chemistry Platform Into New Markets | P2 Science announced it has closed an oversubscribed $23 million funding round led by Sofinnova Partners to accelerate commercial growth and expand its green chemistry platform into new markets. The company said the financing will support t... |
| 19.05.2026 | Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology | Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating ... |
| 11.05.2026 | CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib | CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign... |
| 07.05.2026 | Signadori Bio: €11.1 Million Seed Round Raised For Monocyte Immunotherapy Platform Targeting Solid Tumors | Signadori Bio announced the completion of a seed extension financing round, bringing the company’s total funding to €11.1 million. The latest investment included participation from Taiho Ventures along with existing investors Sofinnova Part... |
| 07.05.2026 | CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple Myeloma | CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma.
The finan... |
| 21.11.2025 | Capital on Tap secures £500M, the second round of speakers for the Tech.eu Summit 2026, and how EQT uses AI | This week, we tracked more than 70 tech funding deals worth over €2.3 billion and over 10 exits, M&A transactions, rumours, and related news stories across Europe.
In addition to this week's top financials, we've also indexed the most i... |
| 19.11.2025 | Sofinnova Partners Closes Oversubscribed Fund XI at €650M for Biotech, MedTech | Sofinnova Partners closed Fund XI at €650M. The fund will back early-stage biopharma and MedTech firms. It surpasses its original target. The fund will invest in Europe and North America. Sofinnova targets unmet clinical needs.
**Sofinnova ... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 18.11.2025 | T-Therapeutics Secures $91 Million to Advance Bispecific Therapies | T-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence.
**T-Therapeutics Secures $91 Million to Advance Bis... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | Sofinnova Partners closes oversubscribed Fund XI at €650m | - |
| 17.11.2025 | Sofinnova Partners secures €650M to back breakthroughs in biopharma and medical technology | Life sciences venture capital firm Sofinnova Partners today announced the close of its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), greatly exceeding its initial target.
Based in Paris, London, and Milan, Sofi... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 17.11.2025 | With over €4 billion in AUM, France’s Sofinnova closes Fund XI at €650 million to double down on MedTech magic | Paris-based VC firm Sofinnova Partners has closed its latest flagship fund, Sofinnova Capital XI, at an impressive €650 million – a haul that surpasses its original target and reinforces its position as a major player in life sciences inves... |
| 14.11.2025 | T-Therapeutics: Series A Extended To $91 Million As It Advances First-In-Class Bispecifics Toward The Clinic | T-Therapeutics has expanded its Series A financing to a total of $91 million after securing an additional $32 million from new and existing investors. The Cambridge-based biotechnology company, which develops next-generation T cell receptor... |
| 13.11.2025 | Cambridge startup T-Therapeutics secures €27.5 million to improve how the immune system targets disease | T-Therapeutics, a British BioTech company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announced the successful expansion of its Series A financing, raising a further €27.5 million (... |
| 11.11.2025 | Qorium: €22 Million Secured To Advance Cultivated Leather Commercialization | Qorium, the Dutch biotechnology company focused on developing cultivated leather, announced that it has raised €22 million in new funding from Invest-NL and LIOF, along with continued support from existing investors Brightlands Venture Part... |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | AAVantgarde: $141 Million Series B Closed To Advance Clinical Programs For Stargardt Disease And Usher 1B Syndrome | AAVantgarde Bio has closed a $141 million (€122 million) Series B financing to advance its lead clinical programs targeting inherited retinal diseases. The financing round was co-led by Schroders Capital, Atlas Venture, and Forbion, with pa... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding.
The round was led by Schroders Capital, as well as existing investors ... |
| 28.10.2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| 27.10.2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| 27.10.2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| 23.10.2025 | Elevara Medicines Raises $70M in Series A Funding | Elevara Medicines, a London, UK-based clinical-stage biotech developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases, closed a $70m Series A financing.
The round was co-led by Forbion and Sofinnova Partners, wit... |
| 20.10.2025 | Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London | PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future o... |
| 15.10.2025 | Mission Therapeutics Raises $13.3M in Funding | Mission Therapeutics, a Cambridge, UK-based clinical-stage biotech developing first-in-class therapeutics that promote cell and organ health by enhancing mitophagy, raised $13.3m in funding.
The financing was led by current investors Pfizer... |
| 13.10.2025 | NanoPhoria Bioscience: €83.5 Million Series A Secured For Advancing Heart Failure Therapy | NanoPhoria Bioscience, a biotech company based in Milan, announced the first close of its €83.5 million Series A financing round. This round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with additional investments f... |
| 06.10.2025 | NanoPhoria closes €83.5 million Series A for its heart failure candidate – one of Italy’s largest 2025 BioTech rounds | Milan-based NanoPhoria Bioscience today announced the successful first close of its €83.5 million Series A financing round – the largest ever Series A round in Italian BioTech history – for its lung-to-heart drug delivery platform.
The roun... |
| 06.10.2025 | NanoPhoria Bioscience Raises €83.5M in Series A Funding | NanoPhoria Biosciences, a Milan, Italy-based biotech company developing a nano-in-micro and lung-to-heart delivery platform, raised €83.5M in Series A funding.
The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, ... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding.
The round was co-led by Sanofi Ventures and Vi... |
| 18.09.2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| 10.09.2025 | One year on from Draghi report: Europe’s innovation future hangs on the 28th Regime | It's hard to believe that this time last year, I was sitting in a shopping mall (waiting for a flight), reading the Draghi report, a European Union report about the future of European competitiveness authored by Mario Draghi, former Italian... |
| 10.09.2025 | Paris’ SafeHeal raises additional €10 million to transform colorectal surgery for cancer patients | French MedTech startup SafeHeal, a medical device innovator transforming colorectal surgery, today announced a €10 million extension of its oversubscribed €35 million Series C financing round.
The extension is led by Asabys Partners through... |
| 07.09.2025 | Galvanize Therapeutics Secures $100M: Revolutionizing Oncology and Chronic Lung Disease Treatment | Galvanize Therapeutics landed a significant $100 million Series C financing. This substantial capital propels its innovative pulsed electric field (PEF) therapies. The Redwood City firm targets critical unmet needs in oncology and chronic l... |
| 06.09.2025 | Galvanize Therapeutics: $100 Million Raised For Advancing Therapies For Cancer And Chronic Lung Disease | Galvanize Therapeutics, a commercial-stage medical technology company developing novel pulsed electric field therapies, has announced the successful close of a $100 million Series C financing round. The round was oversubscribed, reflecting ... |
| 03.09.2025 | Galvanize Therapeutics Raises $100M in Series C Financing | Galvanize Therapeutics, Redwood City, CA-based commercial-stage medical technology company advancing pulsed electric field (PEF) therapies for oncology and chronic lung disease, raised a $100m Series C financing.
The round was led by Sofinn... |
| 03.09.2025 | Galvanize Therapeutics Raises $100 Million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease | Sofinnova Partners leads premier investor syndicate backing Galvanize's breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD.
REDWO... |
| 17.07.2025 | One Biosciences Raises €15M in Series A Funding | One Biosciences, a Paris, France-based precision oncology techbio company, raised €15M in Series A funding.
The round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Poly... |
| 17.07.2025 | One Biosciences raises €15M Series A to advance precision oncology platform | One Biosciences, a precision oncology biotech company pioneering clinical grade single-cell tumour profiling, today announced €15 million Series A financing, bringing the company’s funding to €20 million.
One Biosciences aims to help clinic... |
| 14.07.2025 | Actithera Secures $75.5 Million to Propel Precision Radioligand Therapies | Actithera, a cutting-edge biotech firm, recently secured $75.5 million in oversubscribed Series A funding. This significant capital injection powers their precision radioligand therapy (RLT) initiatives. Funds will advance their lead FAP as... |
| 10.07.2025 | Have You Missed CEE’s Deep Tech Awakening in Zagreb? | Zagreb, CEE, Croatia, EU ~
Company:
Last week, the capital of Croatia became the center of European deep tech innovation. Around 500 key stakeholders from the innovation ecosystem – including investors, technology leaders, scientists, and p... |
| 10.07.2025 | Actithera: $75.5 Million Series A Raised For Transforming Precision Radioligand Therapy | Actithera, a biotech company specializing in radiopharmaceuticals, has secured $75.5 million in an oversubscribed Series A financing round. This funding will help advance their lead FAP (Fibroblast Activation Protein) asset into clinical de... |
| 09.07.2025 | Actithera Raises $75.5M in Series A Funding | Actithera, an Oslo, Norway-, and Cambridge, MA-based radiopharmaceutical biotech company developing radioligand therapies (RLTs), raised $75.5M in Series A funding.
The round was led by M Ventures and new investors Hadean Ventures, Sofinnov... |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases |
GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 08.05.2025 | HAYA Therapeutics: Pioneering the Future of RNA-Guided Therapies | In the world of biotechnology, innovation is the lifeblood. HAYA Therapeutics has just secured a hefty $65 million in Series A funding, a financial boost that could change the landscape of chronic and age-related disease treatment. This fun... |
| 08.05.2025 | HAYA Therapeutics banks $65 million Series A funding |
HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprie... |
| 21.03.2025 | The Biotech Boom and the Opioid Reckoning: A Tale of Two Industries | In the heart of Europe, a new wave of biotech innovation is rising. Sofinnova Partners has closed a €165 million fund, the Sofinnova Biovelocita II. This fund is a beacon for startups, illuminating the path for groundbreaking therapies. It’... |
| 19.03.2025 | Sofinnova Partners: €165M Biotech Acceleration Fund Closed | Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova Biovelocita II. This fund has exceeded its target, successfully raising €165 million, with s... |
| 12.03.2025 | Sofinnova Partners: €1.2 Billion Raised For Advancing Next Wave Of Life Sciences Innovation | Sofinnova Partners – a leading European venture capital firm in life sciences based in Paris, London, and Milan – announced it had raised €1.2 billion across its platform of investment strategies over the past year, including over €1 billio... |
| 04.03.2025 | VC firm Sofinnova brings in €1.2B over a year to fund up to 60 life sciences companies | Up to 60 new life sciences companies are set to benefit from 1.2 billion euros ($1.27 billion) that Sofinnova Partners has raked in over the past year, the European venture capital firm has announced.
Sofinnova Partners—not to be confused w... |
| 16.10.2024 | Mark Post-Founded Qorium Unveils 35x35cm Cultivated Leather Sample as “Tangible Proof” of a Promising Future | Qorium, a Dutch biotech startup founded by cultivated meat pioneer Mark Post, has announced a significant milestone in scaling up the production of cultivated leather.
Qorium’s platform combines specifically developed cultured cells with ti... |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | Asceneuron closes $100 million series C financing round |
Asceneuron SA, a Lausanne-based clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announces its $100 million oversubscribed Series C financing round. The... |
| 09.07.2024 | Endoron Medical: Endograft Stapling Solutions Company Raises $10 Million In Series A Funding | Endoron Medical, a medtech company specializing in innovative endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms, announced the successful closing of its $10 million Series A funding round. This funding r... |
| 16.05.2024 | PCOS infertility treatment developer May Health raises $25M | The startup May Health has gathered $25 million in funding to help continue clinical studies of its less invasive, outpatient procedure for addressing infertility caused by polycystic ovary syndrome, the endocrine disorder commonly known as... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently
The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 20.03.2024 | Cure51 cierra una ronda semilla de €15M liderada por Sofinnova Partners. Participan Hitachi Ventures, Life Extension Ventures y business angels | 20/03/2024
Nota de prensa
CURE51 CAPTA 15 MILLONES DE EUROS EN UNA RONDA SEMILLA PARA DESARROLLAR TRATAMIENTOS INNOVADORES CONTRA EL CÁNCER
La operación está liderada por Sofinnova Partners, con la participación de Hitachi Ventures GmbH, Li... |
| 15.03.2024 | Meet the founder: Bon Vivant’s Stéphane Mac Millan… ‘In the next 10 years, animal-free dairy proteins will be cheaper [than milk proteins from cows]’ | Once upon a time, dairy proteins were made exclusively by lactating mammals. These days, you can produce them in genetically engineered plants or microbes, or even lactating mammary cells grown in a bioreactor.
But is there a market for ‘an... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 21.02.2024 | Bioptimus: Pioneering AI in Biology | Bioptimus, a Paris-based biotech startup, has secured a hefty $35 million in seed funding to propel its groundbreaking AI foundational model focused on biology. Led by CEO Jean-Philippe Vert, the company aims to revolutionize scientific res... |
| 20.02.2024 | Bioptimus raises $35 million seed round to develop AI foundational model focused on biology | There’s a new generative AI startup based in Paris. But what makes Bioptimus interesting is that it plans to apply everything we’ve collectively learned about AI models over the past few years with a narrow, exclusive focus on biology.
The ... |
| 11.01.2024 | Dutch-based cell-cultured leather company Qorium raises funds; appoints former Nike exec as new CEO | Read this article in:
Limburg-based Qorium, a cell-cultured leather company, announced that it has raised fresh funding from Brightlands Venture Partners and Sofinnova Partners.
Additionally, Michael Newton, a former senior executive at Nik... |
| 05.01.2024 |
Stanford Biodesign co-founder joins Sofinnova Partners | Dr. Josh Makower [Image from his LinkedIn page]Sofinnova Partners — a prominent life sciences venture capital firm based in Paris, London, and Milan — has added Stanford Biodesign co-founder and director Dr. Joshua Makower as an advisory ve... |
| 22.12.2023 | 2024 forecast: Will generative AI find what it needs to deliver for patients? | Large language programs such as ChatGPT and its followers have hogged the spotlight this year, leaving their audience calling for new debates on their ethics and safety. But as the medtech industry watches from the wings—hearing that artifi... |
| 15.12.2023 | Is Impact Investing the Future of European Venture Capital Industry? | Key Takeaways:
Sofinnova Partners is a leading Paris-based venture capital firm focussed on investing in the life sciences sector.
The firm manages over €2 billion of assets dedicated to life sciences investing.
Sofinnova Partners takes a l... |
| 13.12.2023 | Sofinnova opens biotech creation ‘toolbox’ as part of Europe-wide strategy | Venture capital firm Sofinnova Partners has launched a new investment strategy specifically aimed at setting up and accelerating biotech startups across Europe.
The strategy, dubbed Biovelocita, will involve a newly formed team assembled wi... |
| 05.12.2023 | Sofinnova Partners Unveils Sofinnova.AI: A Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment Practice | Combination of real time scientific databases with proprietary data will enable venture capital firm to enhance deal origination and portfolio growth through data-driven insights and strengthened entrepreneurial partnerships
Sofinnova Partn... |
| 16.11.2023 | 'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair | When it comes to bringing together pharma and financiers, the U.S. leads the way with industrial-scale events like J.P. Morgan in San Francisco and BIO in San Diego. But for the chairman of European life sciences VC firm Sofinnova Partners,... |
| 26.10.2023 | L’école AI Secures 3 Million USD in Seed Funding for “Machine Teaching” from Sofinnova | The company’s technology, which removes the engineering complexity around AI systems for image analysis, will initially assist medical professionals
L’école AI, creator of ÉO, a “machine teaching” technology that removes the engineering com... |
| 26.10.2023 | Sofinnova Partners Raises $200M Digital Medicine Fund | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, closed its Digital Medicine Fund, at $200M.
Led by Partners Edward Kliphuis, and Simon Turner, the fund targets three main areas: enabling ... |
| 26.10.2023 | Sofinnova Partners closes €190M Digital Medicine I fund; backs L’école AI in a €2.8M deal | Read this article in:
Sofinnova Partners, a life sciences venture capital firm based in Paris, London, and Milan, announced that it has successfully closed Sofinnova Digital Medicine I Fund at €190M, surpassing its target.
Led by Partners E... |
| 08.09.2023 | France-based Gradient Denervation Technologies bag €14M to develop novel pulmonary hypertension therapy | Read this article in:
France-based medtech startup Gradient Denervation Technologies announced on Thursday that it had raised €14M in a Series A round of funding. Asabys Partners led the financing effort through its newly established fund, ... |
| 07.09.2023 | Gradient Denervation Technologies cierra una serie A de €14m liderada por Sabadell Asabys | 07/09/2023
Nota de prensa
GRADIENT DENERVATION TECHNOLOGIES CIERRA UNA SERIE A DE €14M LIDERADA POR SABADELL ASABYS
Gradient Denervation Technologies (“Gradient”), una empresa de dispositivos médicos que desarrolla una solución innovador... |
| 21.06.2023 | Nuage Therapeutics cierra una ronda Seed de €12M liderada por Sofinnova Partners y Asabys. Participan CDTI y BStartup | 21/06/2023
Nota de prensa
NUAGE THERAPEUTICS CIERRA UNA RONDA SEED DE €12M LIDERADA POR SOFINNOVA PARTNERS Y ASABYS. PARTICIPAN CDTI Y BSTARTUP
Nuage Therapeutics (“Nuage”), compañía biotecnológica que desarrolla un motor de descubrimien... |
| 10.05.2023 | Sustainable performance fibers company Werewool raises $3.7 million led by Material Impact and Sofinnova Partners | Werewool won the prestigious ELLE & Polestar Design Towards Zero Award
Our mission as a company is to make the fashion industry compatible with nature.”
— Chui-Lian Lee, Co-founder and CEOBROOKLYN, NY, USA, May 10, 2023/EINPresswire.com... |
| 04.04.2023 | Why Sofinnova is Betting on the Confluence of Digital Technology and the Life Sciences | With the advent and adoption of digital technologies, lines have long blurred among the world of devices, pharma and purely software-driven products. And now, one European venture capital firm has decided to bet on the future of this conver... |
| 31.03.2023 | BioCorteX raises $5 million to unlock drug-bacteria interactions | London-based bio-tech BioCorteX has raised $5 million in Seed funding. The funds will be used to further develop the company's Carbon Mirror platform which is a computer simulation to understand drug-bacteria interactions which hopes to imp... |
| 07.03.2023 | Noema Pharma raises CHF103 million | |
| 12.01.2023 | French pharma Amolyt nets €130 million series C co-led by Sofinnova Partners | Amolyt Pharma, an Ecully, France-based pharma startup working on rare disease treatments, has closed a €130 million series C round.
Amolyt is targeting rare indications affecting the body's hormone supply from endocrine glands. The series C... |
| 11.11.2022 | Sofinnova Partners Appoints Mats Eklund as Partner and Chief Operating Officer | Sofinnova Partners, a life sciences venture capital firm based in Paris, London, and Milan, appointed Mats Eklund as Partner and Chief Operating Officer, effective immediately.
Mr. Eklund will be taking over the helm of Sofinnova’s corporat... |
| 16.05.2022 | VC firm Sofinnova banks $1B from Apollo to invest in early-stage biotech solutions | Biotechs may be seeing their valuations plummet, but Apollo Global Management still wants in. The asset manager has committed up to 1 billion euros ($1.04 billion) in capital commitments to Sofinnova Partners, one of Europe’s largest early-... |
| 06.05.2022 | With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB | Michel Vounatsos
→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highl... |
| 21.11.2021 | Sofinnova Partners Raises €150M for Its Third Industrial Biotech Fund | Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, raised €150m for its third Industrial Biotech Fund.
Sofinnova Industrial Biotech II, which brought the firm’s total assets under management to €2.5 b... |
| 17.11.2021 | VC firm Sofinnova Partners secures €150M to invest in companies leveraging biotech to develop sustainable solutions | Paris-based Sofinnova Partners, a venture capital firm that invests in the life sciences sector from Seed to later-stage, announced that it has secured €150M for its third industrial biotech fund dedicated to environmental impact. With this... |
| 12.11.2021 | GycoEra seals series A financing round at CHF 45 million | |
| 25.10.2021 | Sofinnova Partners Raises €472M to Form Early-Stage Healthcare VC Fund | Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, closed its latest early-stage healthcare venture capital fund, Sofinnova Capital X, at €472 ($548) million.
Capital X, the 10th iteration of Sofinnov... |
| 19.10.2021 | Instacart’s largest acquisition yet is a $350 million bet on cashierless, in-store shopping | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
One factor that will help keep this current fervid pace of dealmaking, even as lock-down orders f... |
| 20.09.2021 | Рискованные инвестиции: разбираемся, стоит ли игра свеч | Рискованные инвестиции: разбираемся, стоит ли игра свеч |
| 20.09.2021 | Risky investments: is the game worth the candle? | Risky investments: is the game worth the candle? |
| 20.09.2021 | Рискованные инвестиции: разбираемся, стоит ли игра свеч | Рискованные инвестиции: разбираемся, стоит ли игра свеч |
| 31.08.2021 | Here’s how French medtech Tissium uses biopolymers for tissue reconstruction; raises €50M | Paris-based Tissium, a privately-owned medtech company that develops biomorphic programmable polymers for tissue reconstruction, announced that it has raised €50M in its Series C round of funding.Investors in this round
The round was led by... |
